treprostinil / Generic mfg. - LARVOL DELTA

Case Report: A case of severe pulmonary hypertension combined with FBN1 mutation associated geleophysic dysplasia. (PubMed, Front Pediatr) - "Treprostinil may be effective in the treatment of these patients. Given the risk of progressive pulmonary disease, early surgical intervention for mitral valve pathology may be crucial for improving prognosis."

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • FBN1

TETON: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P3 | N=576 | Active, not recruiting | Sponsor: United Therapeutics | Trial completion date: Jun 2025 ➔ Jan 2026 | Trial primary completion date: Jun 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

Unmasking an Intracardiac Shunt in a Case of Persistent Unexplained Hypoxia: A Case Report. (PubMed, Reports (MDPI)) - "Right heart catheterization (RHC) revealed precapillary pulmonary hypertension (88/37/54 mmHg), prompting the initiation of intravenous epoprostenol. The patient was eventually discharged with a treatment regimen that included subcutaneous Treprostinil. It is important to recognize that the consequences of PH are extensive, and that a rare yet significant etiology for persistent hypoxemia may be attributed to right-to-left shunting."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hypertension • Nephrology • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases

Level 3 Cardiopulmonary Exercise Testing to Guide Therapeutic Decisions in Non-Severe Pulmonary Hypertension with Lung Disease. (PubMed, Life (Basel)) - "In contrast, the static PVR group remained clinically stable. These observations suggest that an exercise-induced increase in PVR, identified through Level 3 CPET, may help select patients with non-severe PH-ILD who are more likely to benefit from early initiation of inhaled treprostinil."

Journal • Cardiovascular • Hypertension • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Winning With Four: Hemodynamic and Symptomatic Improvement of Pulmonary Arterial Hypertension With Contemporary Quadruple Therapy. (PubMed, JACC Case Rep) - "Managing pulmonary arterial hypertension in patients with multiple comorbidities is challenging and requires a multidisciplinary approach with aggressive upfront therapy leading to significant symptomatic and hemodynamic improvement."

Journal • Cardiovascular • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Reverse Bernheim Phenomenon - A True Enigma. (PubMed, Respir Med Case Rep) - "He was treated with ambrisentan, sildenafil and selexipag. The patient's PAH therapy was subsequently escalated with addition of intravenous treprostinil, which led to improvement of exercise capacity and resolution of syncopal episodes. A repeat stress echocardiogram revealed resolution of the acute exercise-induced RV dilatation and septal bulging without compressing the LVOT."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Hypotension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Efficacy of inhaled treprostinil versus PDE5 inhibitors and no treatment in ILD-PH (ERS 2025) - No abstract available

Clinical • Interstitial Lung Disease

Real-life use of inhaled treprostinil in pulmonary hypertension associated with interstitial lung disease (ERS 2025) - No abstract available

Clinical • Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Inhaled Treprostinil treatment in pulmonary hypertension associated with interstitial lung disease in an outermost region of Europe. (ERS 2025) - No abstract available

Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

TETON-PPF clinical trial of inhaled treprostinil for the treatment of progressive pulmonary fibrosis (ERS 2025) - No abstract available

Clinical • Immunology • Pulmonary Disease • Respiratory Diseases

TETON phase 3 clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis (ERS 2025) - No abstract available

Clinical • P3 data • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Randomized, Placebo-Controlled Trial of Peri-Operative Treprostinil in Pediatric Patients Undergoing the Fontan Operation. (PubMed, Pulm Circ) - "Peri-operative subcutaneous TRE did not reduce CTD or hospital LOS after Fontan operation and did not exert significant beneficial effects on post-operative hemodynamics. Accordingly, TRE at a dose of 10 ng/kg/min is not recommended for routine use in immediate post-operative Fontan management."

Journal • Cardiovascular • Heart Failure • Pediatrics

Intraoperative Management of Adult Congenital Heart Disease: A Multidisciplinary Approach to Managing Severe Right Heart Failure and Pulmonary Hypertension (ASA 2025) - "HemoSphere monitoring and TEE were used, with inhaled nitric oxide and IV Treprostinil available. Through a detailed, "zero fail mission" approach, complex congenital heart disease with severe right heart failure and pulmonary hypertension was safely managed intraoperatively."

Clinical • Anesthesia • Cardiovascular • Congestive Heart Failure • Heart Failure • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

From Confusion to Medfusion: Adapting a Nurse-Friendly, Hospital-Friendly, Intuitive Pump for Delivery of Subcutaneous Treprostinil in the Pediatric Inpatient Setting (PHA-PHPN 2025) - No abstract available

Clinical • Pediatrics

Practical Considerations for Managing Patients on Tyvaso DPI (Treprostinil Inhalation Powder). (PubMed, Pulm Circ) - "This review provides an overview of inhaled prostacyclin therapy with a focus on practical considerations for managing PAH and PH-ILD patients treated with Tyvaso DPI. Recommendations from a panel of pulmonary hypertension advanced practice providers include patient selection, education, communication, onboarding and monitoring, transition and titration, side effect mitigation, and the availability of clinician- and patient-facing resources."

Journal • Review • Cardiovascular • Hypertension • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Outpatient Intravenous Dobutamine as Right Ventricular Support During Inhaled Prostacyclin Uptitration in Severe PH-ILD. (PubMed, Pulm Circ) - "The INCREASE trial demonstrated the successful use of inhaled treprostinil, but slow uptitration delays the effects. Our study suggests outpatient IV dobutamine as interim support, improving contractility and reducing PVR during uptitration."

Journal • Cardiovascular • Hypertension • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

EFFICACY AND SAFETY OF INHALED TREPROSTINIL IN GROUP 3 PULMONARY HYPERTENSION: A SYSTEMATIC REVIEW (CHEST 2025) - No abstract available

Clinical • Review • Cardiovascular • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

LEVEL THREE CARDIOPULMONARY EXERCISE TESTING AS A DECISION-MAKING TOOL FOR INHALED TREPROSTINIL THERAPY IN NONSEVERE PULMONARY HYPERTENSION-INTERSTITIAL LUNG DISEASE (CHEST 2025) - No abstract available

Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

DEVELOPMENT AND VALIDATION OF A SCORING SYSTEM FOR PREDICTION OF TOLERANCE TO INHALED TREPROSTINIL IN PATIENTS WITH PAH OR PH-ILD (CHEST 2025) - No abstract available

Clinical • Interstitial Lung Disease

IMPACT OF INHALED TREPROSTINIL INITIATION TIMING ON HOSPITALIZATIONS IN PATIENTS WITH PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (CHEST 2025) - No abstract available

Clinical • Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

1032: PH-ILD Controversies: A Pro-Con Debate (CHEST 2025) - "2. All patients with PH-ILD should be treated with inhaled treprostinil"

Interstitial Lung Disease

SAPPHIRE: Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension (clinicaltrials.gov) - P2 | N=10 | Recruiting | Sponsor: University of Florida | Trial completion date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jan 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Sarcoidosis

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Yuh Chin T Huang, MD, MHS

New P1 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Efficacy and Safety of Selexipag Treatment in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease. (PubMed, Life (Basel)) - "While other systemic agents used in PAH have not shown as much success as inhaled treprostinil in treating PH-ILD, our case series highlights the potential role of selexipag in patients with concomitant CTD-PAH and ILD. Further investigation of selexipag in pure Group 3 PH-ILD patients is warranted."

Journal • Cardiovascular • Hypertension • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Rheumatology

Therapeutic options for patients with pulmonary hypertension and interstitial lung disease. (PubMed, Ther Adv Respir Dis) - "In contrast, inhaled treprostinil was shown effective in the INCREASE Trial, a placebo-controlled study in which patients with PH-ILD treated with inhaled treprostinil demonstrated a 31-meter placebo-corrected improvement in the primary endpoint, 6-minute walk distance...Strategy and innovations for early detection and diagnosis are highlighted while underscoring the importance of early detection and diagnosis. A holistic and collaborative approach to the treatment of PH-ILD is outlined including a variety of adjunctive measures and the consideration of patient-reported outcome data in order to improve disease management outcomes."

Journal • Review • Cardiovascular • Hypertension • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases